WHAT YOU NEED TO KNOW Last week, CAPA hosted an online panel on the importance of balancing the needs of innovation, access, and affordability when it comes to drug policy. The panel entitled, “Drug Pricing Debate: Why Drug Innovation, Access & Affordability Matter More Than Ever During COVID-19” welcomed discussion with leading experts in the […]

Continue Reading

IN CASE YOU MISSED IT: This week, Morning Consult published an op-ed by Matthew Lane, executive director of the Coalition Against Patent Abuse, around reforming the patent system to balance competition and innovation so that American patients have access to affordable drugs, especially as both the private and public sectors work to quickly discover a treatment for COVID-19.  […]

Continue Reading

IN CASE YOU MISSED IT: Recently, HealthAffairs highlighted a study by researchers at Brigham and Women’s Hospital and Harvard Medical School that showed the real effects of name-brand drug manufacturers maintaining their market exclusivity by preventing of generic competition from entering the marketplace.  Among 61 name-brand drugs at risk of losing their market exclusivity from 2010-2016, 45 […]

Continue Reading

IN CASE YOU MISSED IT: This week, Townhall published an op-ed by Wayne Brough, President of the Innovation Defense Foundation, on the challenging task policymakers have in thwarting threats that could hinder the nation’s economic recovery from COVID-19.  As we work as a nation to financially rebuild, lawmakers must also consider the constrains that bad patent laws can have […]

Continue Reading

WHAT YOU NEED TO KNOW Recently, Barron’s highlighted a study that showed how biosimilars of AbbVie’s Humira have saved Europe a bundle.  Biosimilar versions of the antibody product adalimumab have taken some of Humira’s market in Europe and other countries, dropping AbbVie’s foreign sales of Humira by 27% last year. “Biosimilar versions of the antibody product adalimumab […]

Continue Reading